$AnaptysBio(ANAB.US)$ NEWS Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) Positive Significant improvement in skin clearance for patients receiving imsidolimab in the Phase 3 trials Excellent maintenance of skin clearance with no flares in patients on monthly maintenance dosing of imsidolimab Positive safety and tolerability profile with no treatment-related serious adverse events reported Low incidence ...
$AnaptysBio(ANAB.US)$ NEWS Anaptys To Receive $50 Mln In Capped Non-Recourse Monetization From Amended Agreement With Sagard In Exchange For Additional Jemperli Royalties
Despite a recent rebound, AnaptysBio's share price is far from regaining investors' confidence after substantial losses over the past five years. Market fears over consistent lack of profitability persist, despite revenue growth.
$AnaptysBio(ANAB.US)$Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) HALT off at 8:30 AM est
AnaptysBio股票討論區
NEWS
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
Positive
Significant improvement in skin clearance for patients receiving imsidolimab in the Phase 3 trials
Excellent maintenance of skin clearance with no flares in patients on monthly maintenance dosing of imsidolimab
Positive safety and tolerability profile with no treatment-related serious adverse events reported
Low incidence ...
NEWS
Anaptys To Receive $50 Mln In Capped Non-Recourse Monetization From Amended Agreement With Sagard In Exchange For Additional Jemperli Royalties
$CG Oncology(CGON.US)$ Phase 3
$美國聯合醫療(UTHR.US)$ Phase 3
$美國聯合醫療(UTHR.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Insmed(INSM.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$烏龍製藥(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Jaguar Health(JAGX.US)$ Phas...
$Intra-Cellular Therapies(ITCI.US)$ Phase 3
$CG Oncology(CGON.US)$ Phase 3
$和黃醫藥(HCM.US)$ Phase 3
$Viracta Therapeutics(VIRX.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$烏龍製藥(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Marinus Pharmaceuticals(MRNS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3...
• $Box Inc(BOX.US)$: Morgan Stanley Upgrades to Overweight from Equalweight - PT $34 (from $32)
• $CF工業控股(CF.US)$: RBC Capital Upgrades to Outperform from Sector Perform - PT $135 (from $110)
• $New Gold(NGD.US)$: RBC Capital Upgrades to Outperform from Sector Perform - PT $1.25 (from $1)
• $Sensei Biotherapeutics(SNSE.US)$: Oppenheimer Upgrades to Outperform from Perform - PT $5
• $Senetas Corp Ltd(SEN.AU)$ : Tru...
暫無評論